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Introduction
Ewing sarcoma (ES) is a highly malignant tumor composed 
of small round cells. The origin of this tumor was unclear 
until recently, when electron microscopic and immunohis-
tochemical analyses suggested that it is of neurogenic ori-
gin [1–3]. ES tumors often express a balanced translocation 
involving the EWS gene on chromosome 22 and a member 
of the ETS family of transcription factors [4, 5]. With the 
development of diagnostic radiological techniques such as 
magnetic resonance imaging (MRI), extraskeletal masses 
can be depicted clearly and the tumor area can be accurately 
evaluated. Due to improvements in intensive chemotherapy, 
the prognosis of ES patients has improved markedly [6–16]. 
The current chemotherapy protocols used to treat ES include 
various combinations of the following six drugs: doxorubicin 
(DOX), cyclophosphamide (CPM), vincristine (VCR), actin-
omycin-D (ACT-D), ifosfamide (IFO), and etoposide (ETO). 
Local ES lesions are usually treated via surgical excision or 
radiotherapy, or a combination of both. In cases in which 
surgical excision is not possible due to the large size of the 
tumor, its anatomical location, or the fact that the acquired 
surgical margin is not sufficient to achieve local control, pre- 
or postoperative radiotherapy is usually selected [14]. Bet-
ter understanding of how local control can be achieved has 
helped to improve the oncological outcomes of ES. Although 
the survival rate of ES patients has improved, their prognosis 
remains unsatisfactory, and the treatment of ES is still chal-
lenging to the medical teams involved, which include ortho-
pedic surgeons, pediatric oncologists, and radiotherapists.
This review was undertaken to update our current 
knowledge regarding the diagnosis and treatment of ES. 
The author hopes that this article will help to summarize 
the latest findings about ES for treatment teams and lead to 
further improvements in the prognosis of ES.
Abstract Ewing sarcoma (ES) is rare in Japanese people, 
and only 30–40 patients develop the disease annually. To 
diagnose ES, molecular techniques that aim to detect char-
acteristic fusion genes are commonly used in combination 
with conventional histological and immunohistochemical 
examinations. The treatment strategy for ES is character-
ized by multi-disciplinary collaboration between pediatric 
oncologists, medical oncologists, radiation oncologists, 
and orthopedic surgeons. In recent years, numerous large-
scale national or international multi-institutional studies of 
ES have been performed. Pre- and postoperative intensive 
systemic chemotherapy with multiple anticancer drugs is 
the standard treatment method for ES. Depending on the 
obtained surgical margin, postoperative radiation might 
also be performed. If preoperative radiological examina-
tions indicate that surgical excision would be difficult, pre-
operative radiation can be administered. As the treatment 
outcomes of ES have improved, late complications and sec-
ondary malignancies have become a problem. After treat-
ment, patients with ES require very long-term follow-up in 
order to detect secondary malignancies and growth-related 
musculoskeletal complications.
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History of ES
Lücke is considered to have been the first to describe this 
small round cell tumor [17, 18]. In 1918, Stout et al. [19] 
reported an undifferentiated round cell tumor that origi-
nated in the ulnar nerve and exhibited rosette formation, 
and he later proposed the concept of neuroepithelioma [20].
In 1921, Ewing reported a round cell sarcoma of the 
radius in a 14-year-old girl as a “diffuse endothelioma 
of bone” [21]. Radiotherapy produced a good response 
according to physical and plain X-ray examinations. In his 
report, Ewing reviewed six similar cases that he had expe-
rienced in the previous 4 months [21]. Ewing also docu-
mented the following specific radiographic findings: “A 
large portion or the whole of the shaft is involved, but the 
ends are generally spared. The shaft is slightly widened, but 
the main alteration is a gradual diffuse fading of the bone 
structure. Bone production is entirely absent”. Many of the 
features of ES described by Ewing in his original report are 
still very important, even after 90 years.
Angervall and Enzinger were the first to report the exist-
ence of ES of extraskeletal origin [22]. In 1976, Nesbitt and 
Vidone described a neuroepithelioma as a primitive neu-
roectodermal tumor (PNET) [23]. Since the latter report, 
the name PNET has been commonly used instead of neu-
roepithelioma. Askin et al. [24] described a small round 
cell tumor that originated in the thoracopulmonary region 
in 1979. In 1984, Jaffe et al. [1] reported a PNET of the 
bone composed of small round cells that exhibited rosette 
formation and were positive for the neural marker neuron-
specific enolase.
In the 1980s, chromosome analysis detected the t(11;22)
(q24;q12) translocation in ES cell lines [25, 26]. The 
EWS-FLI1 chimeric gene, which is produced by a bal-
anced translocation between FLI1 on chromosome 11q24 
and EWS on chromosome 22q12, was identified in 1992 
after the cloning of translocation breakpoints [5]. As the 
abovementioned small round cell tumors; i.e., ES, PNET, 
neuroepithelioma, and Askin’s tumor, exhibit similar types 
of chromosomal translocation, e.g., t(11;22)(q24;q12), they 
are classified as a single disease entity; i.e., the ES family 
of tumors. In this review paper, the name ES is used for all 
of these tumors.
Characteristics of ES
ES is the second most common bone tumor in childhood 
and adolescence. In Japan, approximately 30–40 patients 
with ES of the bone are registered in the bone tumor reg-
istry run by the Japanese Orthopaedic Association (JOA) 
Musculoskeletal Tumor Committee annually [27]. Males 
are affected more frequently than females (ratio 3:2). The 
peak age of ES patients ranges from 10 to 24 years (Fig. 1).
A total of 188 cases of ES of the bone were registered 
between 2006 and 2011 [27]. The sites that are most com-
monly affected by ES of the bone are the pelvis, ribs, and 
femur (Table 1). By comparison, 138 extraskeletal ES were 
registered in the same period, with 65 of these affecting 
males and 73 affecting females. The sites that were most 
frequently affected by extraskeletal ES were the thigh, glu-
teal region, back, lower leg, and the retroperitoneal region 
[28].
At the time of the diagnosis of ES of the bone, 34 % 
of patients had distant metastases and 5 % had regional 
lymph node metastases [27]. At the time of the diagnosis of 
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Fig. 1  The age distribution of patients with ES of the bone (blue bar) and extraskeletal ES (red bar) [27, 28]
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extraskeletal ES, 29 % had distant metastases and 12 % had 
regional lymph node metastases [28].
The incidence of ES differs markedly among races [29]; 
i.e., ES is rare among black children [29–31] and the Chi-
nese population [29]. Conversely, Caucasian children dis-
play a 6 times higher incidence of ES than black children 
[32]. The ratio of ES to osteosarcoma is around 0.5 among 
Caucasians in the United States and less than 0.15 among 
non-Caucasian children in Shanghai, Beijing, and the 
United States [29]. Among Japanese patients, the ratio of 
ES of the bone to osteosarcoma was 0.21 [27].
Symptoms and blood and serum findings
Patients with ES exhibit local symptoms such as tumor 
mass formation, induration, pain, swelling, venous dilation, 
and hyperemia. Pathological fractures sometimes occur due 
to bone metastasis, and spinal metastasis-associated back 
pain can progress to spinal paralysis. In cases in which an 
ES originates in the chest wall, pleural infiltration com-
bined with carcinomatous pleurisy is often observed. The 
interval between the onset of the initial symptom and diag-
nosis has become shorter; i.e., it was 4.7 months in 2003, 
whereas it was 9.6 months in 1984 [33]. This change might 
have been due to improvements in diagnostic techniques.
Anemia and leukocytosis are often observed in ES, as 
are increases in the white blood cell count, blood sedi-
mentation rate; and the serum levels of lactate dehydroge-
nase (LDH), alkaline phosphatase, and C-reactive protein. 
An elevated LDH level is associated with a poor progno-
sis [33]. Physicians must be aware that ES patients often 
exhibit similar blood and serum biochemical findings to 
those displayed by patients with inflammatory conditions 
such as osteomyelitis.
Radiological findings
In ES of the bone, plain radiographs exhibit permea-
tive and infiltrative destruction of the affected bone (often 
in the diaphysis of the long bone) (Fig. 2). In addition, 
an onion skin-like appearance and spiculae are indica-
tive of periosteal reactions. The pelvis is the most com-
monly affected site; however, it is difficult to identify pel-
vic tumors on plain X-rays alone. Computed tomography 
(CT) is useful for depicting extraskeletal soft tissue masses, 
destruction of the bone cortex, and pulmonary metastasis 
(Fig. 3). On MRI, ES of the bone exhibits low signal inten-
sity on T1-weighted images and high signal intensity on 
T2-weighted images, and appears as large extraskeletal soft 
tissue masses derived from bone. Skip lesions affecting the 
bone are often clearly depicted on MRI. On bone scans, ES 
of the bone demonstrates high 99mTc-MDP uptake. Simi-
larly, it displays high 18F-fluorodeoxy glucose (18F-FDG) 
uptake on 18F-FDG-positron emission tomography (PET), 
[34] (Fig. 4).
From a radiological point of view, the differential diag-
noses of ES include osteomyelitis, Langerhans cell histio-
cytosis, skeletal metastatic neuroblastoma, and malignant 
lymphoma of the bone.
Histology
Histologically, ES is composed of sheets of uniform 
small round tumor cells with round nuclei and little cyto-
plasm that do not exhibit matrix formation (Fig. 5a). ES 
tumor cells are characterized by uniform findings with few 
mitoses. ES also demonstrates morphological features that 
are indicative of neural differentiation, such as rosette for-
mation. Since ES tumor cells contain abundant amounts of 
Table 1  ES in Japan (2006–2011)
Data are derived from the Bone Tumor Registry in Japan, 2011 [27], and the Soft Tissue Tumor Registry in Japan, 2011 [28], run by the JOA 
Musculoskeletal Tumor Committee
Bone 188
 Cranium 2 Skull 1, mandible 1
 Trunk 112 Pelvis 43, ribs 29, spine 23, scapula 9, clavicle 6 and sternum 2
 Upper extremities 13 Humerus 10, ulna 2 and phalanges 1
 Lower extremities 50 Femur 25, tibia 10, fibula 10, tarsals 3 and metatarsals 2
 Multiple sites 11
Soft tissue 138
 Head and neck 12 Head 5, neck 3, face 3 and maxilla 1
 Trunk 68 Gluteal region 11, back 10, retroperitoneal 9, lower back 8, inguinal region 8, thorax 7, 
pleural cavity 4, axilla 3, abdomen 3, shoulder 2, abdominal cavity 2 and perineal region 1
 Upper extremities 12 Upper arm 4, hand 4, elbow 2 and forearm 2
 Lower extremities 41 Thigh 30, lower leg 10 and foot 1
 Multiple sites 5
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glycogen, periodic acid-Schiff (PAS)-positive granules are 
seen in their cytoplasm. Immunohistochemically, positiv-
ity for neural markers such as S-100 protein and PGP9.5 
is sometimes detected, and vimentin positivity is also 
commonly observed. In over 90 % of ES cases, positiv-
ity for CD99, a product of the MIC2 gene, is detected on 
Fig. 2  A 38-year-old woman with ES of the right tibia. a Plain X-ray 
showing permeative bone destruction. MRI detected a tumor that dis-
played b, low signal intensity and c, heterogeneous high signal inten-
sity on T1- and T2-weighted imaging, respectively. The tumor was 
located both around and within the tibia. This case was presented by 
Dr Akira Kawai, Department of Musculoskeletal Oncology and Reha-
bilitation, National Cancer Center Hospital, Tokyo, Japan
Fig. 3  A 16-year-old patient with ES of the ilium. a A radiolucent 
lesion was visible in the right ilium on a plain X-ray (arrowhead). b 
CT detected a large mass that exhibited a periosteal reaction in the 
right ilium (arrowhead) and c, T2-weighted MRI depicted a mass that 
displayed heterogeneous high signal intensity in and around the right 
ilium and acetabulum
Fig. 4  A 9-year-old girl with ES developed a metastasis in her left 
ischium. a T2-weighted MRI (T2-STIR) demonstrated an area of 
high signal intensity in the ischium, and 18F-FDG-PET detected high 
18F-FDG uptake in the same region
Fig. 5  Histology of ES. a ES involves the sheet-like proliferation of 
small round cells with little cytoplasm (hematoxylin-eosin stain). b 
Periodic acid-Schiff staining detected small positive granules, which 
were considered to be glycogen molecules
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the cytoplasmic membrane (Fig. 6) [35]; however, CD99 
expression is not specific to ES, as it is also detected in 
synovial sarcoma [36], lymphoblastic leukemia, lym-
phoma, and other tumors [4]. Atypical ES, a variant of ES 
composed of large cells, has also been reported [37, 38]. 
In addition, ES composed of spindle-shaped and adaman-
tinoma-like cells, as well as other variants have also been 
reported [39].
Fusion gene analysis
In recent years, molecular techniques have been commonly 
used to diagnose ES because it often exhibits specific chro-
mosomal translocations. Reverse transcription polymerase 
chain reaction (RT-PCR) and fluorescent in situ hybridiza-
tion (FISH) are very useful methods for detecting fusion 
genes (Fig. 7). Table 2 shows the most common chromo-
somal translocations found in ES. The EWS-FLI1 fusion 
gene, which is caused by the t(11;22)(q24;q12) translo-
cation, is the most common type of fusion gene: 85 % of 
ES tumors that exhibit the EWS gene rearrangement were 
found to possess this type of translocation [4, 5, 26].
EWS-ERG, which is caused by the t(21;22)(q22;q12) 
translocation, is observed in 10 % of cases [40, 41]. Other 
rare fusion genes include: EWS-ETV1, which is caused by 
the t(7;22)(q22;q12) translocation [42]; EWS-ETV4, which 
is caused by the t(17;22)(q21;q12) translocation [43, 44]; 
and EWS-FEV, which is caused by the t(2;22)(q35;q12) 
translocation [45]. These fusion products encode chimeric 
proteins that function as aberrant oncogenic transcription 
factors. Other cytogenetic abnormalities have also been 
reported [33, 46]. Subjecting bone marrow aspiration sam-
ples to RT-PCR might be useful for detecting fusion genes 
in the bone marrow of ES patients. Kunisada et al. [47] 
reported that 2 of 5 patients without radiologically detect-
able metastasis (M0) possessed fusion genes in their bone 
marrow.
Fig. 6  Membranous expression of CD99, a product of the MIC2 
gene, is observed in ES cells
EWS  translocation
RT-PCR
Test sample     Positive control Negative control
1: EWS-FLI1 ex6
2: EWS-FLI1 ex9
1 2 1 2 1 2
Marker
Dual color FISH
a
b
Fig. 7  a RT-PCR. The left lane shows a marker, and the next three 
pairs of lanes (in a left-to-right direction) show the test samples, posi-
tive controls, and negative controls (1: EWS-FLI1 ex6, 2: EWS-FLI1 
ex9), respectively. This figure shows that the test sample was positive 
for both EWS-FLI1 ex6 and EWS-FLI1 ex9, which means that the 
tumor possessed the EWS-FLI1 ex6 fusion gene. b FISH. An abnor-
mal cell that has been hybridized with the Vysis LSI EWSR1 (22q12) 
dual color, break apart rearrangement probe. In a normal cell that 
lacks a t(22q12) translocation in the EWSR1 gene region, two fusion 
signals will be observed, reflecting the presence of two intact cop-
ies of EWSR1. The cell in this image shows one fusion, one orange, 
and one green signal, which is indicative of the rearrangement of one 
copy of the EWSR1 gene region
Table 2  Most common types of translocations found in Ewing 
sarcoma
Translocation Fusion gene % of tumors exhibiting EWS 
gene rearrangement
t(11;22)(q24;q12) EWSR1-FLI1 85
t(21;22)(q22;q12) EWSR1-ERG 10
t(7;22)(q22;q12) EWSR1-ETV1 rare
t(17;22)(q21;q12) EWSR1-ETV4 rare
t(2;22)(q35;q12) EWSR1-FEV rare
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The most common fusion gene involves the in frame 
fusion of exon 7 of the EWS gene with exon 6 of the FLI1 
gene (the type 1 fusion gene). When the prognosis of 147 
ES patients was examined according to fusion gene type in 
the Cooperative ES Study (CESS), patients with the type 1 
fusion gene were reported to have a better prognosis than 
patients with other types of fusion gene [48]. In addition, 
in a study by the Memorial Sloan Kettering Cancer Center 
the 64 patients with the type 1 fusion gene exhibited a bet-
ter prognosis than the 35 patients with other types of fusion 
gene [49]. However, in 1999 Ginsberg examined 136 cases 
of ES and found that patients with the EWS-FLI1 and 
EWS-ERG fusion genes had similar clinical courses [50]. 
In a recent prospective study (the European Ewing Tumor 
Working Initiative National Groups 99 study; the Euro-
EWING 99 study), which examined 565 patients with pri-
mary ES tumors (1999–2007), including 296 patients with 
type 1 fusion genes and 269 patients with other types of 
fusion genes, a prospective evaluation did not find that the 
type 1 fusion gene confers a prognostic benefit [51]. In ES, 
the accumulation of genetic aberrations involving several 
genes on different chromosomes seems to have a greater 
influence than fusion gene type on the biological and clini-
cal behavior of ES.
Treatment
Radiotherapy had been the standard treatment for ES, 
and until the 1960s radiotherapy or surgery were the only 
treatments for ES [15]. ES is currently treated in a mul-
tidisciplinary manner involving chemotherapy, surgery, 
and radiotherapy. If a tumor is considered to be difficult 
to excise with an adequate margin, preoperative radio-
therapy involving 36–55 Gy is administered. Similarly, 
postoperative radiotherapy is performed if the margin 
achieved by surgery is inadequate for local control.
According to the bone tumor registry developed by the 
JOA [27], 173 of 188 patients with ES of the bone received 
treatments including chemotherapy, including 65 patients 
who underwent chemotherapy and surgery; 50 patients who 
received chemotherapy and radiotherapy; and 32 patients 
who were treated with chemotherapy, surgery, and radio-
therapy (Fig. 8).
In the 1960s, a maximum of 10 % of ES patients 
survived [15], and VCR (a vinca alkaloid), ACT-D (an 
antitumor antibiotic), CPM (an alkylating agent), and 
DOX (an antitumor antibiotic) started to be included 
in treatment protocols for ES. After the 1980s, IFO (an 
alkylating agent) and ETO (a vinca alkaloid) were added 
to such protocols [15]. Currently, the 5-year overall sur-
vival rate of ES patients is approximately 60 % [10, 11, 
14, 50, 52].
Chemotherapy
The purpose of preoperative chemotherapy is (1) to eradi-
cate any micrometastases that exist at the time of diagnosis, 
(2) to reduce the volume of the tumor in order to facilitate 
its excision, and (3) to provide information that will aid 
the selection of anti-tumor drugs for postoperative chemo-
therapy. In the USA, the Memorial Sloan-Kettering Cancer 
Center has developed a few treatment protocols for ES [7]. 
In addition, Rosen et al. [7] described an effective chemo-
therapy regimen called T-11.
IESS-1 (the Intergroup ES Study), which included 
331 patients, compared the prognosis of patients that 
were treated with the VAC regimen (VCR, ACT-D, and 
CPM) and that of patients that were administered the 
VAC + DOX (VACD) regimen [8] (Table 3). As a result, 
it was found that the addition of DOX had a beneficial 
effect on patient survival. Patients treated with the VAC 
regimen alone, the VAC regimen and whole lung irradia-
tion, or the VACD regimen alone exhibited 5-year disease-
free survival rates of 24, 44, and 60 %, respectively. IESS-
II, which included 293 patients, reported that patients that 
were treated with an intensified VACD regimen displayed 
a 5-year disease-free survival rate of 68 %, whereas that of 
the patients treated with a moderate dose VACD regimen 
was 48 % [9]. NCI INT-0091 (1988–1992) was a prospec-
tive randomized trial of a single VDC-containing regimen 
(VCR, DOX, and CPM) versus the administration of VDC 
and the IE regimen (IFO + ETO) [10]. The 5-year disease-
free survival rate was 54 % in the VDC group and 69 % in 
the VDC + IE group; thus, VDC + IE had a significantly 
positive effective on patient survival in localized cases 
compared with VDC. The main concept behind this regi-
men was adopted by the Japanese Ewing Sarcoma Study 
(JESS) 04 protocol.
In recent years, the results of the AEWS0031 study per-
formed by the Children’s Oncology Group, which included 
Fig. 8  Treatments employed in 188 cases of ES (2006–2011). The 
data shown are derived from the Bone Tumor Registry in Japan, 
2010, run by the JOA Musculoskeletal Tumor Committee
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587 patients, were reported [11]. The latter study prospec-
tively compared the effects of VDC + IE between regimens 
involving administration intervals of 3 and 2 weeks. The 
5-year disease-free survival rate was 65 % in the 3-week 
interval group and 73 % in the 2-week interval group 
(p = 0.048), and there was no difference in the incidence of 
toxicities between the 2 groups. At present, the administra-
tion of VDC + IE using a short administration interval is 
regarded as the standard chemotherapy regimen for treating 
ES in the USA.
In the CESS, a large-scale European study, 81 of 93 
patients were treated with the VACD regimen, and the 
5-year survival rate was 55 % (Table 4). The 5-year sur-
vival rate was 80 % in cases of tumor volume of <100 ml 
and was 31 % in cases of tumor volume ≥100 ml [12]. 
In the CESS-86 study, which included 301 patients, the 
VACD regimen was used to treat patients with tumor vol-
umes of <100 ml, and the VAID regimen, in which the 
CPM included in the VACD regimen was replaced with 
IFO, was administered to patients with tumor volumes of 
≥100 ml [13]. The 10-year disease-free survival rate was 
52 % in the standard risk group treated with VACD and 
51 % in the high risk group administered VAID. Thus, the 
VAID regimen was effective at increasing the survival of 
high risk patients. In the EICESS-92 study, which included 
647 patients, patients with tumor volumes of <100 ml were 
randomly assigned to receive either the VAID or VACD 
regimen, and patients with tumor volumes of ≥100 ml 
with/without metastasis (including skip metastasis) were 
randomly assigned to receive either the VAID or EVAID 
Table 3  Studies of Ewing sarcoma conducted in the USA
VAC: VCR + ACT-D + CPM
VACD: VAC + DOX
VDC: VCR + DOX + CPM
IE: IFO + ETO
Study Author No. of patients Chemotherapy 5-year relapse-free survival (%)
IESS-I Nesbit et al. [8] 331 VAC 24
VAC + whole lung RT 44
VACD 60
IESS-II Burgert et al. [9] 293 VACD (intensified) 68
VACD (moderate) 48
NCI INT-0091 Grier et al. [10] 200 VDC 54
198 VDC + IE 69
COG AEWS0031 Womer et al. [11] 587 VDC + IE 3-week interval 65 (5 year-EFS)
VDC + IE 2-week interval 73 (5 year-EFS)
Table 4  Studies of Ewing sarcoma conducted in Europe
SR Standard risk, HR high risk (definitions are provided in the literature)
VACD: VAC (VCR + ACT-D + CPM) + DOX
VAID: VAI (VCR + ACT-D + IFO) + DOX
EVAID: VAID + ETO
VIDE: VCR + IFO + DOX + ETO
Study Author No. of patients Protocol Disease-free survival (%)
CESS81 Jürgens et al. [12] 93 VACD 80 (volume <100 ml) (5-year)
31 (volume ≥100 ml) (5-year)
CESS86 Paulussen et al. [13] 301 SR: VACD 52 (10-year)
HR: VAID 51 (10-year)
EICESS92 Paulussen et al. [14] 647 SR: VAID/VACD 68/67 (5-year)
HR: VAID/EVAID 44/52 (5-year)
EURO-EWING99 Le Deley et al. [16] 856 Randomization in SR (R1 arm)
6 VIDE + 1 VAI
 + 7VAC(n = 431) or 75 (3-year)
 +7VAI (n = 425) 78 (3-year)
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regimen [14]. In the standard risk group, the 5-year dis-
ease-free survival rate was 68 % in the VAID group and 
67 % in the VACD group. Therefore, in the standard risk 
group CPM had a similar effect on event-free survival to 
IFO; however, it was also associated with increased toxic-
ity. In the high risk group, the 5-year disease-free survival 
rate was 44 % in the VAID group, and adding ETO to the 
VAID regimen resulted in an increase in the survival rate to 
52 % in the EVAID group. Therefore, it was confirmed that 
ETO had a beneficial effect among high risk patients. In 
recent years, the Euro-EWING 99 study examined the util-
ity of induction treatment with the VIDE regimen and one 
postoperative cycle of the VAI regimen [16]. Patients with 
localized disease or lung metastasis were classified into 
the R1 or R2 arm. The patients in the R1 group were ran-
domly assigned to receive the VAC or VAI regimen, and the 
patients in the R2 group were randomly assigned to receive 
the VAI regimen or busulfan and melphalan after one post-
operative cycle of VAI. In the R1 group, which contained 
856 patients, it was found that there was no difference in 
survival between the VAC and VAI groups.
On the other hand, Obata et al. [52] conducted a Japa-
nese study involving 243 patients from 29 institutions who 
exhibited a mean follow-up period of 66 months. Of the 
243 patients, 183 underwent definitive surgery as the pri-
mary local treatment. The treatment protocols included 
many different regimens such as the T-11 and modified 
T-11 regimens in 47 patients, V(A)CD + IE-based regi-
mens in 41 patients [10, 53, 54], the VAID/EVAID regimen 
in 22/3 patients [13, 14], and VACD-based regimens in 22 
patients [9, 12], etc. In addition, high-dose chemotherapy 
with hematopoietic stem cell rescue was performed in 51 
patients. In patients with localized disease (M0), the 5-year 
overall survival rate was 55 %, and the event-free survival 
rate was 47 %. In patients with metastatic disease (M1), 
the 5-year overall survival rate was 13 %, and the event-
free survival rate was 7 %. The following characteristics 
were found to be associated with a poor prognosis: age 
≥16 years, M1 disease, and a tumor located in the trunk 
[52]. The Japanese ES Study (JESS) group has not pub-
lished the final results of the JESS04 study; however, satis-
factory results have been obtained in similarly large studies 
conducted in the USA and Europe.
Intensive treatment
Meyers et al. [55] reported the results of intensive treat-
ment in 32 patients with bone or bone marrow metastasis 
from ES . If a good response was obtained after 5 cycles 
of induction chemotherapy composed of a 3-drug regimen 
(CPM, DOX, and VCR) alone or the same 3-drug regimen 
combined with an additional 2-drug regimen (IFO and 
ETO), consolidation therapy including high-dose melpha-
lan, ETO, and whole body irradiation was performed fol-
lowed by stem-cell support. The event-free 2-year survival 
rate of all 32 cases was 20 %, and that of the 23 cases that 
received stem-cell support was 24 %; i.e., the latter regi-
men failed to improve the survival of high risk patients.
The treatment results for primary disseminated mul-
tifocal ES, excluding single pulmonary metastases that 
were present at diagnosis, were also reported in the Euro-
EWING 99 trial [56]. In this group, 6 cycles of the VIDE 
regimen were administered preoperatively and then local 
therapy involving surgery and/or radiotherapy was per-
formed. After one postoperative cycle of the VAI regimen 
had been administered, high-dose busulfan-melphalan was 
administered followed by an autologous stem cell trans-
plantation (HDT/SCT). The median follow-up period was 
3.8 years, and the 3-year disease-free survival rate was 
27 %.
Patients with pulmonary metastasis are administered 
chemotherapy based on the first-line regimens for patients 
without metastasis. Single pulmonary metastases can be 
controlled with intensive chemotherapy; however, the 
prognosis of patients with bone or bone marrow metastasis 
remains poor.
Local treatment: radiotherapy and tumor excision
As ES is sensitive to radiotherapy, radiotherapy was per-
formed as a local treatment before the introduction of 
chemotherapy. It was reported that ES is usually treated 
with radiation doses ranging from 36 to 60 Gy [12, 14, 57]. 
Two irradiation techniques are commonly used to treat ES. 
Definitive radiotherapy aims to destroy all viable tumor 
cells and is used to treat centrally located lesions, such as 
those located in the spinal column (Fig. 9). On the other 
hand, pre- or postoperative adjuvant radiotherapy is admin-
istered in cases in which the risk of local relapse is con-
sidered to be high, e.g., because an insufficient margin was 
acquired or it is considered that a safe margin would be 
difficult to obtain. In the CESS86 study [57], 46 Gy were 
delivered to patients with positive surgical margins, and 
60 Gy were delivered to the non-surgical group. There was 
no significant difference in the treatment results of the two 
groups; thus, 60 Gy successfully obtained local control of 
ES.
Several studies have detected higher local relapse rates 
after radiotherapy alone than after combined therapy involv-
ing surgery and radiotherapy. In the CESS studies, the local 
control rate obtained in the patients who received definitive 
radiotherapy was significantly worse than that achieved in 
the patients who underwent surgery with/without additional 
radiotherapy [58]. Bacci et al. [59] reported that the local 
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control rate of ES was 100 % in patients who underwent 
surgery and radiotherapy and 67 % in patients that were 
treated with radiotherapy alone. Wilkins et al. [60] found 
that the 5-year survival rate of patients that received radio-
therapy alone as a local treatment was 27 %, whereas that of 
the patients treated with radiation and surgery was 72 %. In 
patients with ES, surgery improves the safety of local con-
trol. As for safe surgical margins, it has been suggested that 
tumors must be excised together with 2 cm of normal tis-
sue [61]. In other sarcomas, membranous structures around 
the tumor can function as a barrier against tumor extension; 
however, the barrier function of such structures seems to be 
insufficient to prevent growth in ES.
In 2003, based on the results of the CESS and EICESS 
trials, Schuck et al. [62] reported that postoperative radi-
otherapy improves local control in poor responders to 
chemotherapy, even after wide resection . Currently, the 
standard treatment strategy for surgically accessible pri-
mary lesions is to surgically resect the tumor as much as 
possible together with a safe margin, although radiotherapy 
might be selected depending on the surgical margin and the 
histological effects of chemotherapy. If a tumor is inoper-
able, radiotherapy alone is employed as a local treatment. 
After radiotherapy, it might be possible to surgically excise 
previously inoperable tumors together with a safe margin.
The author thinks that radiotherapy is not necessary after 
adequate wide excision in cases involving patients that 
respond well to preoperative chemotherapy. However, the 
author considers that radiotherapy should be added after 
inadequate excision and in cases involving poor responders 
to chemotherapy or excessively narrow surgical margins.
Among patients who exhibited pulmonary metastasis at 
diagnosis, the patients who received total lung irradiation 
were found to have a better prognosis than those who did 
not undergo such treatment [63, 64]. A dose of 14–18 Gy is 
recommended for total lung irradiation [63]. However, cli-
nicians should be aware that more than 50 % of ES patients 
have functional lung abnormalities [64].
In recent years, carbon ion beam treatment has prevailed 
in Japan [65], and it is often used to achieve local control of 
surgically inaccessible tumors due to anatomical reasons. 
However, when a tumor can be surgically excised without 
a 
b 
c d 
Fig. 9  An 18-year-old girl had a 1-month history of back pain with-
out any obvious cause and experienced muscle weakness in both 
legs The patient suffered numbness and urinary disturbances. a Plain 
X-ray showing the loss of spinous processes at the T5 level (arrow). 
b CT detected a spotted osteolytic lesion in the lamina of the T5 ver-
tebra. c T2-weighted MRI showed a mass that exhibited iso-signal 
intensity and was compressing the spinal cord from the posterior 
direction (arrow). d Emergent decompression of the T4-6 vertebrae 
was performed to rescue the spinal cord from compression. Preop-
erative chemotherapy composed of VDC + IE was performed, 45 Gy 
radiation was administered as a local treatment, and VDC-IE was 
administered as a post-local therapy. The patient became completely 
free from spinal palsy and was able to walk without any support. She 
has been disease-free for 6 years after the local treatment
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causing a reduction in function or quality of life, surgery 
should be selected.
Reconstructive surgery
It is very important to prevent surgical site infections in ES 
patients: if an infection occurs, postoperative chemotherapy 
must be postponed until the infection has been completely 
eradicated. In recent years, the dose intensity of chemo-
therapy has been increasing, which could lead to an increase 
in the infection rate. Orthopedic surgeons should not select 
reconstruction methods that are associated with high infec-
tion rates. In recent years, liquid nitrogen-treated recycled 
bone has been developed and has since been used frequently 
[66]. This method is reported to induce a cryo-immuno-
logical response [67] so it might be expected to result in a 
higher survival rate than other reconstruction methods.
The pelvis is the most frequent site for ES and patients 
with pelvic ES have a poor prognosis [68]. Fibula strut 
grafts are available for pelvic reconstruction after iliac exci-
sion (P1). Non-vascularized fibula grafts seem to be suffi-
cient for pelvic reconstruction because bone union can be 
expected to occur within a few months after their implanta-
tion [69]. The author is currently examining the utility of 
hip joint transposition in cases involving large tumors of 
the iliac wing that affect the acetabulum [70, 71], and so 
far no postoperative surgical site infections have occurred 
in any patient. In a study of cases in which local control of 
pelvic ES was obtained using internal hemipelvectomy, the 
patients reported that they had a good postoperative quality 
of life [72].
The prompt administration of intensive chemotherapy 
is important in ES. Most ES patients are aged between 10 
and 20 years of age. Although the reconstruction of skel-
etal defects using tumor prostheses might be an estab-
lished treatment after tumor excision, if available biologi-
cal reconstruction methods seem to be more suitable than 
tumor prostheses for cases involving children.
Metastasis and secondary malignancies
A total of 34 % of ES patients exhibit metastasis at diag-
nosis [27]. Patients with lung metastasis alone, display a 
better prognosis than patients with bone or bone marrow 
metastases. As the survival rate of ES has increased, cases 
of late relapse, e.g., relapses that occur more than 10 years 
after treatment, are being reported (Fig. 10). No standard 
treatment strategy for relapsed ES has been established. 
Fig. 10  A 10-year-old boy with ES of the right humerus. He had a 
pain in his right upper arm. A plain X-ray showed a limited periosteal 
reaction. a T1-weighted MRI depicted an area of heterogeneous low 
signal intensity in the humerus. b A bone scan showed abnormally 
high isotope uptake in the right humerus. After the diagnosis of ES 
had been confirmed by open biopsy, preoperative chemotherapy 
composed of DOX, CPM, methotrexate, VCR, IFO, and ACT-D was 
administered. c After the preoperative chemotherapy, the patient 
underwent wide excision of the tumor in his right humerus. A sling 
procedure involving a vascularized fibula graft was performed for 
reconstruction, and postoperative chemotherapy was initiated. At 
13 years after surgery, he visited our hospital due to dyspnea and 
coughing. A chest X-ray showed a white region in his right lung, and 
d CT depicted a large amount of pleural effusion and atelectasis due 
to the pulmonary metastasis of ES
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There have been several trials of the ICE regimen (IFO, 
carboplatin, and ETO) [73], topotecan + CPM [74], and 
the irinotecan (CPT-11) plus temozolomide regimen [75].
In the EICESS92 study, which examined 647 cases, the 
frequency of secondary malignancies was 0.9 % among 
all cases and 1.2 % among patients that were with treated 
with ETO. On the other hand, none of the patients that 
were treated without ETO developed secondary malignan-
cies [76]. In the Italian Sarcoma Group Experience study 
(1983–2006), which involved 543 ES patients that exhib-
ited a median follow-up period of 86 months, secondary 
malignancies developed in 15 patients (3 %). Among the 
latter patients, the median interval between the diagnosis 
of the primary and secondary malignancies was 84 months. 
In another study, the cumulative frequency of second-
ary malignancies was 3.4 % after 10 years, 4.7 % after 
20 years, and 5 % after 25 years [77]. In the follow-up 
period, tumor relapses, secondary malignancies, and late 
complications such as leg length discrepancies or scoliosis 
after thoracic surgery or radiation can all have important 
impacts on survival and quality of life (Fig. 11).
Further improving the cure rate
Increasing the dose intensity of anti-tumor drugs, e.g., via 
their bi-weekly administration, might lead to improvements 
in patient prognosis. New drugs such as pazopanib [78], 
eribulin [79], and trabectedin [80, 81] are becoming avail-
able and might lead to further increases in patient survival. 
Of course, controlling treatment complications and the 
early detection and prevention of secondary malignancies 
are mandatory. In Japan, single institutional trials are not 
sufficient for producing scientific evidence, as they would 
involve too few patients; however, the multi-institutional 
study being conducted by the JESS group is expected to 
produce high quality data.
Summary
The prognosis of ES patients has improved in recent 
years. To diagnose ES, molecular techniques that aim to 
detect characteristic fusion genes are commonly used in 
Fig. 11  A 1-year-old boy suddenly suffered a pain in his right lower 
leg without any obvious cause. a A plain X-ray showed a radiolucent 
lesion and widening of the diaphysis of his right tibia. A periosteal 
reaction was also observed. b T2-weighted imaging demonstrated an 
area of high signal intensity in the tibia. An open biopsy resulted in a 
diagnosis of ES of the tibia. After preoperative chemotherapy com-
posed of 6 courses of VIDE according to the protocol outlined in 
the Euro-EWING 99 study, radiotherapy involving 55.8 Gy was per-
formed as a local therapy. After the radiotherapy, one course of the 
VAI regimen and 7 courses of the VAC regimen were administered. 
When the patient was 9.5 years old, CT detected lymph node swell-
ing in his neck. A biopsy of the lymph node demonstrated metastasis 
from papillary thyroid cancer. The patient underwent excision of his 
right thyroid lobe and the swollen lymph node. c He displayed a 5-cm 
leg length discrepancy at 10 years after the local therapy
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combination with conventional histological and immuno-
histochemical techniques. As for chemotherapy, several 
new lines of evidence have been obtained in large-scale 
studies conducted in Europe and North America. The use 
of multidisciplinary treatment teams composed of special-
ists from various fields such as pediatric oncologists, medi-
cal oncologists, radiation oncologists, and orthopedic sur-
geons is necessary to further improve patient prognosis. 
After treatment, ES patients must be carefully followed up 
for tumor relapses, growth-related musculoskeletal compli-
cations, and secondary malignancies.
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